Veterinary Active Pharmaceutical Ingredients (API) - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509243866

Publication Date:

September 3, 2024

Pages:

131

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Active Pharmaceutical Ingredients are the substances used in the fabrication of pharmaceutical drugs responsible for beneficial health effects produced by use of the product. An example of an API in veterinary medicine would be trimethoprim-sulfadoxine contained in the products Borgal, Trivetrin, or Trimidox.
The global market for Veterinary Active Pharmaceutical Ingredients (API) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
According to Our PET Supplies Research Center, the global pet industry reached $ 261 billion in 2022, a year-on-year increase of 11.3%. The United States gains the highest pet penetration rate and becomes the largest pet market. According to the American Pet Products Association (APPA), 66% of American households keep pets, and the total industry sales was about US$136.8 billion, an increase of 10.8% over 2021. According to IVH, the German pet products industry association, the number of pets in Germany reached 33.4 million in 2022, with a total turnover of nearly 鈧�6.5 billion. The 2023 China Pet Industry Trend Insight White Paper released by JD shows that the market size of the four major pet physical commodities is increasing year by year: pet supplies account for 45%, pet staple food accounts for nearly 35%, pet snacks account for 12%, and pet medicine and health care account for 146%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Veterinary Active Pharmaceutical Ingredients (API), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Veterinary Active Pharmaceutical Ingredients (API) by region & country, by Type, and by Application.
The Veterinary Active Pharmaceutical Ingredients (API) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Veterinary Active Pharmaceutical Ingredients (API).
麻豆原创 Segmentation
By Company
Alivira Animal Health Ltd
Qilu Pharmaceutical (Inner Mongolia) Co, Ltd
Procyon Life Sciences
SUANFARMAOfichem Group
NGL Fine-Chem Ltd
Huvepharma
Jiangsu Lingyun Pharmaceutical Co. Ltd
Excel Veterinary HealthcareVetpharma(Insud Pharma)
Menadiona
lndukern Group
LasaSupergenerics Ltd.
Segment by Type:
Chemical Based API
Biological API
Highly Potent APl(HPAPI)
Segment by Application
CDMO
CMO
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Veterinary Active Pharmaceutical Ingredients (API) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Veterinary Active Pharmaceutical Ingredients (API) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Veterinary Active Pharmaceutical Ingredients (API) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Veterinary Active Pharmaceutical Ingredients (API) Product Introduction
1.2 Global Veterinary Active Pharmaceutical Ingredients (API) 麻豆原创 Size Forecast
1.2.1 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value (2019-2030)
1.2.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume (2019-2030)
1.2.3 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Price (2019-2030)
1.3 Veterinary Active Pharmaceutical Ingredients (API) 麻豆原创 Trends & Drivers
1.3.1 Veterinary Active Pharmaceutical Ingredients (API) Industry Trends
1.3.2 Veterinary Active Pharmaceutical Ingredients (API) 麻豆原创 Drivers & Opportunity
1.3.3 Veterinary Active Pharmaceutical Ingredients (API) 麻豆原创 Challenges
1.3.4 Veterinary Active Pharmaceutical Ingredients (API) 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Veterinary Active Pharmaceutical Ingredients (API) Players Revenue Ranking (2023)
2.2 Global Veterinary Active Pharmaceutical Ingredients (API) Revenue by Company (2019-2024)
2.3 Global Veterinary Active Pharmaceutical Ingredients (API) Players Sales Volume Ranking (2023)
2.4 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Company Players (2019-2024)
2.5 Global Veterinary Active Pharmaceutical Ingredients (API) Average Price by Company (2019-2024)
2.6 Key Manufacturers Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Veterinary Active Pharmaceutical Ingredients (API) Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Veterinary Active Pharmaceutical Ingredients (API)
2.9 Veterinary Active Pharmaceutical Ingredients (API) 麻豆原创 Competitive Analysis
2.9.1 Veterinary Active Pharmaceutical Ingredients (API) 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Veterinary Active Pharmaceutical Ingredients (API) Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Veterinary Active Pharmaceutical Ingredients (API) as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Chemical Based API
3.1.2 Biological API
3.1.3 Highly Potent APl(HPAPI)
3.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Type
3.2.1 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value, by Type (2019-2030)
3.2.3 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value, by Type (%) (2019-2030)
3.3 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Type
3.3.1 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume, by Type (2019-2030)
3.3.3 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume, by Type (%) (2019-2030)
3.4 Global Veterinary Active Pharmaceutical Ingredients (API) Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 CDMO
4.1.2 CMO
4.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Application
4.2.1 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value, by Application (2019-2030)
4.2.3 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value, by Application (%) (2019-2030)
4.3 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Application
4.3.1 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume, by Application (2019-2030)
4.3.3 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume, by Application (%) (2019-2030)
4.4 Global Veterinary Active Pharmaceutical Ingredients (API) Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Region
5.1.1 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Region (2019-2024)
5.1.3 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Region (2025-2030)
5.1.4 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Region (%), (2019-2030)
5.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Region
5.2.1 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Region (2019-2024)
5.2.3 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Region (2025-2030)
5.2.4 Global Veterinary Active Pharmaceutical Ingredients (API) Sales Volume by Region (%), (2019-2030)
5.3 Global Veterinary Active Pharmaceutical Ingredients (API) Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
5.4.2 North America Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
5.5.2 Europe Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
5.6.2 Asia Pacific Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
5.7.2 South America Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
5.8.2 Middle East & Africa Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Veterinary Active Pharmaceutical Ingredients (API) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Veterinary Active Pharmaceutical Ingredients (API) Sales Value
6.2.1 Key Countries/Regions Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
6.2.2 Key Countries/Regions Veterinary Active Pharmaceutical Ingredients (API) Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
6.3.2 United States Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
6.4.2 Europe Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
6.5.2 China Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
6.6.2 Japan Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
6.7.2 South Korea Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
6.8.2 Southeast Asia Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Veterinary Active Pharmaceutical Ingredients (API) Sales Value, 2019-2030
6.9.2 India Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Veterinary Active Pharmaceutical Ingredients (API) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Alivira Animal Health Ltd
7.1.1 Alivira Animal Health Ltd Company Information
7.1.2 Alivira Animal Health Ltd Introduction and Business Overview
7.1.3 Alivira Animal Health Ltd Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Alivira Animal Health Ltd Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.1.5 Alivira Animal Health Ltd Recent Development
7.2 Qilu Pharmaceutical (Inner Mongolia) Co, Ltd
7.2.1 Qilu Pharmaceutical (Inner Mongolia) Co, Ltd Company Information
7.2.2 Qilu Pharmaceutical (Inner Mongolia) Co, Ltd Introduction and Business Overview
7.2.3 Qilu Pharmaceutical (Inner Mongolia) Co, Ltd Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Qilu Pharmaceutical (Inner Mongolia) Co, Ltd Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.2.5 Qilu Pharmaceutical (Inner Mongolia) Co, Ltd Recent Development
7.3 Procyon Life Sciences
7.3.1 Procyon Life Sciences Company Information
7.3.2 Procyon Life Sciences Introduction and Business Overview
7.3.3 Procyon Life Sciences Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Procyon Life Sciences Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.3.5 Procyon Life Sciences Recent Development
7.4 SUANFARMAOfichem Group
7.4.1 SUANFARMAOfichem Group Company Information
7.4.2 SUANFARMAOfichem Group Introduction and Business Overview
7.4.3 SUANFARMAOfichem Group Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.4.4 SUANFARMAOfichem Group Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.4.5 SUANFARMAOfichem Group Recent Development
7.5 NGL Fine-Chem Ltd
7.5.1 NGL Fine-Chem Ltd Company Information
7.5.2 NGL Fine-Chem Ltd Introduction and Business Overview
7.5.3 NGL Fine-Chem Ltd Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.5.4 NGL Fine-Chem Ltd Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.5.5 NGL Fine-Chem Ltd Recent Development
7.6 Huvepharma
7.6.1 Huvepharma Company Information
7.6.2 Huvepharma Introduction and Business Overview
7.6.3 Huvepharma Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Huvepharma Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.6.5 Huvepharma Recent Development
7.7 Jiangsu Lingyun Pharmaceutical Co. Ltd
7.7.1 Jiangsu Lingyun Pharmaceutical Co. Ltd Company Information
7.7.2 Jiangsu Lingyun Pharmaceutical Co. Ltd Introduction and Business Overview
7.7.3 Jiangsu Lingyun Pharmaceutical Co. Ltd Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Jiangsu Lingyun Pharmaceutical Co. Ltd Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.7.5 Jiangsu Lingyun Pharmaceutical Co. Ltd Recent Development
7.8 Excel Veterinary HealthcareVetpharma(Insud Pharma)
7.8.1 Excel Veterinary HealthcareVetpharma(Insud Pharma) Company Information
7.8.2 Excel Veterinary HealthcareVetpharma(Insud Pharma) Introduction and Business Overview
7.8.3 Excel Veterinary HealthcareVetpharma(Insud Pharma) Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Excel Veterinary HealthcareVetpharma(Insud Pharma) Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.8.5 Excel Veterinary HealthcareVetpharma(Insud Pharma) Recent Development
7.9 Menadiona
7.9.1 Menadiona Company Information
7.9.2 Menadiona Introduction and Business Overview
7.9.3 Menadiona Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Menadiona Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.9.5 Menadiona Recent Development
7.10 lndukern Group
7.10.1 lndukern Group Company Information
7.10.2 lndukern Group Introduction and Business Overview
7.10.3 lndukern Group Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.10.4 lndukern Group Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.10.5 lndukern Group Recent Development
7.11 LasaSupergenerics Ltd.
7.11.1 LasaSupergenerics Ltd. Company Information
7.11.2 LasaSupergenerics Ltd. Introduction and Business Overview
7.11.3 LasaSupergenerics Ltd. Veterinary Active Pharmaceutical Ingredients (API) Sales, Revenue and Gross Margin (2019-2024)
7.11.4 LasaSupergenerics Ltd. Veterinary Active Pharmaceutical Ingredients (API) Product Offerings
7.11.5 LasaSupergenerics Ltd. Recent Development
8 Industry Chain Analysis
8.1 Veterinary Active Pharmaceutical Ingredients (API) Industrial Chain
8.2 Veterinary Active Pharmaceutical Ingredients (API) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Veterinary Active Pharmaceutical Ingredients (API) Sales Model
8.5.2 Sales Channel
8.5.3 Veterinary Active Pharmaceutical Ingredients (API) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Alivira Animal Health Ltd
Qilu Pharmaceutical (Inner Mongolia) Co, Ltd
Procyon Life Sciences
SUANFARMAOfichem Group
NGL Fine-Chem Ltd
Huvepharma
Jiangsu Lingyun Pharmaceutical Co. Ltd
Excel Veterinary HealthcareVetpharma(Insud Pharma)
Menadiona
lndukern Group
LasaSupergenerics Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.